Joint Scientific Consultation EU Strategies for Medical Device Companies

The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their development pathways with evolving EU expectations and reduce downstream evidence gaps. Insights from the EU HTA Regulation webinar for health technology developers on June 19, 2026 highlight the growing importance of this early engagement.

Early Alignment Before Formal Review

The Joint Scientific Consultation EU operates as a non-binding pre-submission mechanism under the EU HTA Regulation, enabling health technology developers to receive concrete advice on study design, endpoints, and population criteria. This early engagement helps companies address anticipated HTA requirements before pivotal trials begin.

Rigorous Selection and Timelines

Selection follows strict criteria that favour technologies meeting unmet medical needs, first-in-class innovations, substantial patient or system impact, cross-border relevance, or Union research priorities. The process runs on a quarterly intake schedule, moving from eligibility screening and briefing-package submission through structured dialogue to a confidential outcome document delivered within roughly four-and-a-half months.

Limited Access for High-Risk Devices

Only Class III implantable devices, certain Class IIb active therapeutic devices, and Class D in-vitro diagnostics qualify, with just two to five device slots planned annually in the initial years. Parallel consultation with expert panels is encouraged for breakthrough products, and practical experience from medicinal-product JSC rounds shows that complete briefing materials and early PICO mapping markedly improve procedural efficiency.

Actionable Intelligence for Market Access

For HEOR and market-access teams, the insights gained sharpen clinical-development and health-economic strategies, lowering the risk of evidence shortfalls during subsequent joint clinical assessments. Although advice reflects scientific understanding at a single moment in time, proactive participation equips developers with clearer expectations for evidence synthesis, outcome selection, and study validity as the EU HTA system matures.